BSE to discontinue trading in Ranbaxy from April 6

The BSE has decided to delist Ranbaxy scrip from S&P BSE 100, S&P BSE 200, S&P BSE 500, S&P BSE Healthcare and S&P BSE Carbonex indices from April 6.
After Ranbaxy's merger with Sun Pharma, the scrip will be discountinued from trading on the bourses, while Ranbaxy shareholders will receive 0.8 share of Sun Pharma for each share of Ranbaxy, the BSE said in a statement today.
BSE will include Bosch Ltd in S&P BSE 100, Gujarat Gas Co Ltd in S&P BSE 200 and Global Offshore Services in S&P BSE 500, replacing Ranbaxy from April 6, the BSE statement said.

The BSE has also decided to include AGI Infra and Mahabir Metallex in S&P BSE SME IPO indices effective from March 30, the statement said.